Drug Trial News

RSS

Omalizumab outperforms oral immunotherapy in treating multi-food allergy

A clinical trial has found that the medication omalizumab, marketed as Xolair, treated multi-food allergy more effectively than oral immunotherapy (OIT) in people with allergic reactions to very small amounts of common food allergens.

2 Mar 2025

First-ever clinical trials evaluate fenofibrate as treatment for HPV-related cancers

A team from University Hospitals Seidman Cancer Center is launching the nation's first-ever clinical trials evaluating the cholesterol drug fenofibrate (Triglide, Fibricor, Lipofen) as an investigational and potential treatment for patients with HPV+ cervical and HPV+ head and neck cancer (HNSCC).

28 Feb 2025

Drug may offer new hope for preventing migraines in kids and teens

For children and teens living with migraine, there may be a new preventive treatment, according to a preliminary study released today, February 26, 2025, that will be presented at the American Academy of Neurology's 77th Annual Meeting taking place April 5–9, 2025, in San Diego and online.

26 Feb 2025

Scientists pioneer fecal transplant capsules to enhance pancreatic cancer treatment

Scientists at Lawson Research Institute (Lawson) of St. Joseph's Health Care London and London Health Sciences Centre Research Institute (LHSCRI) are the first in the world to study fecal transplants using capsules containing microbes from the gut of healthy volunteers to improve the response of patients with advanced pancreatic cancer to chemotherapy.

26 Feb 2025

New drug ataciguat shows promise for managing aortic valve stenosis

Aortic valve stenosis (AVS) is a significant health concern affecting over 1.5 million Americans and millions more globally.

24 Feb 2025

New clinical trial seeks alternatives for head and neck cancer patients unable to use cisplatin

A physician-scientist at the University of Oklahoma is part of an international effort seeking new options for patients with head and neck cancer who cannot receive the standard chemotherapy drug cisplatin.

21 Feb 2025

Inhalable gene therapy tested for cystic fibrosis treatment in the UK and Europe

An inhalable medicine with the potential to improve lung disease in people with cystic fibrosis, irrespective of their mutation type, is being tested in human trials in the UK and Europe.

20 Feb 2025

Vimseltinib gains FDA approval for treating tenosynovial giant cell tumor

The U.S. Food and Drug Administration (FDA) has approved vimseltinib (RomvimzaTM) for adult patients with a rare condition called tenosynovial giant cell tumor (TGCT). TGCT is a tumor of the tissue that lines the joints.

20 Feb 2025

Radiation and immunotherapy help preserve bladders in patients with muscle-invasive bladder cancer

Patients with localized muscle-invasive bladder cancer (MIBC) who received radiation plus the immune checkpoint inhibitors (ICIs) durvalumab (Imfinzi) and tremelimumab (Imjudo) had durable responses that allowed for bladder preservation, according to results from the IMMUNOPRESERVE clinical trial.

18 Feb 2025

Sotagliflozin could be used to reduce the risk of deadly cardiovascular events, trial shows

Sotagliflozin, a drug recently approved by the Food and Drug Administration to treat type 2 diabetes and kidney disease with additional cardiovascular risk factors, can significantly reduce heart attack and stroke among these patients, according to results from an international clinical trial led by a Mount Sinai researcher.

14 Feb 2025

UVA receives $9.3 million NIH grant for ketamine seizure treatment trial

University of Virginia Brain Institute and School of Medicine researchers have received an initial $9.3 million award from the National Institutes of Health for a $30 million clinical trial to determine if the powerful anesthetic ketamine can save patients from prolonged, life-threatening grand mal seizures that won't respond to other treatments.

14 Feb 2025

Low-dose semaglutide reduces alcohol consumption and cravings in early trial

Research reveals semaglutide's effectiveness in decreasing alcohol consumption and cravings, highlighting its potential for treating alcohol use disorder.

13 Feb 2025

Selkirk Pharma introduces ClinFAST™ to expedite fill/finish for clinical trials

Selkirk Pharma, Inc., a privately held U.S. pharmaceutical manufacturer specializing in the fill and finish of injectable drugs, including vaccines and biological therapeutics, today announced the launch of ClinFAST™, a paradigm-shifting service designed to assist clinical stage biotech and pharma companies with a rapid fill/finish process for clinical trial supplies.

13 Feb 2025

University of Michigan tests novel mechanical heart pump in clinical trial

A cardiac surgery and heart failure team at the University of Michigan implanted a novel mechanical heart pump into a patient as part of a clinical trial that will compare it to the only device currently used to treat end-stage heart failure.

12 Feb 2025

NIH clinical trial examines investigational therapy for dengue

A clinical trial supported by the National Institutes of Health (NIH) is testing an experimental treatment designed to help people suffering the effects of dengue, a mosquito-borne viral disease.

11 Feb 2025

AIM Vaccine submits mRNA RSV vaccine for FDA clinical trials

AIM Vaccine Co., Ltd., a leading PRC vaccine company, announced today that its independently developed mRNA RSV (respiratory syncytial virus) vaccine has recently been submitted for clinical trials to the U.S. Food and Drug Administration (FDA).

10 Feb 2025

Neoantigen vaccine sparks powerful immune defense against kidney cancer

A personalized neoantigen cancer vaccine generated strong immune responses in renal cell carcinoma patients, leading to long-lasting T cell expansion and no disease recurrence after 40 months.

6 Feb 2025

New nasal vaccine for COVID-19 set to begin clinical trial in the U.S.

A nasal vaccine for COVID-19 – based on technology developed at Washington University in St. Louis – is poised to enter a phase 1 clinical trial in the U.S. after an investigational new drug application from Ocugen, Inc. was approved by the Food and Drug Administration (FDA). Ocugen, a U.S.-based biotechnology company, licensed the innovative technology from WashU in 2022.

5 Feb 2025

Breakthrough personalized vaccine shows promising results in kidney cancer trial

Dana-Farber Cancer Institute researchers report that all nine patients in a clinical trial being treated for stage III or IV clear cell renal cell carcinoma (a form of kidney cancer), generated a successful anti-cancer immune response after initiation of a personalized cancer vaccine.

5 Feb 2025

International trial aims to prevent Alzheimer’s in high-risk young adults

The first participants in an international clinical trial aimed at preventing Alzheimer's disease in young adults at high risk of the disease have been enrolled.

4 Feb 2025